Serge Belanger
Analyst, Needham and Company
Replay available
CorMedix Inc. (NASDAQ: CRMD) Q1 2026 earnings conference call, held 2026-05-14. Replay captured from the company's public earnings webcast.

Analyst, Needham and Company
EVP and Chief Financial Officer
Analyst, Citizens
Analyst, Gabelli
Analyst, Lyric Partners
EVP and Chief Operating Officer
Chairman and Chief Executive Officer
Analyst, HC Wainwright
LifeSci Advisors
Welcome to the Corps Medics First Quarter 2026 Earnings and Corporate Update Conference Call. Today's conference call is being recorded. There will be a question and answer session at the end of today's presentation and instructions on how to ask a question will be given at that time. At this time, I would like to turn the conference call over to Dan Ferry from LifeSci Advisors. Please go ahead. Good morning and welcome to the Corps Medics First Quarter 2026 Earnings and Corporate Update Conference Call. Leading the call today is Joe Tedisco, Chairman and Chief Executive Officer of Corps Medics. And he is joined by Liz Hurlburt, EVP and Chief Operating Officer, and Susan Blum, EVP and Chief Financial Officer. In addition, Seth Zelnick-Coffin, EVP and Chief Legal and Compliance Officer and Corporate Secretary, Mike Seckler, EVP and Chief Commercial Officer, and Dr. Matt David, EVP and Chief Business Officer, are also on the line and will be available during the Q&A session. Before we begin, I would like to remind everyone that during the call, management may make what are known as forward-looking statements within the meeting set forth in the Private Securities Litigation Reform Act of 1995. These statements are statements other than statements of historical fact regarding management's expectations, beliefs, goals, and plans about the company's prospects and future financial position. Actual results may differ materially from the estimates and projections on which these statements are based due to a variety of important factors, including the risks and uncertainties described in greater detail in CoreMedix filings with the SEC, which are available free of charge at the SEC's website or upon request from CoreMedix. CoreMedix may not actually achieve the goals or plans ...